Trials / Completed
CompletedNCT03763877
A Study of the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD
A Randomized, Double-blind, Placebo-controlled, Parallel Group Trial to Assess the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 121 (actual)
- Sponsor
- Poxel SA · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the efficacy and safety of 3 doses of PXL770 versus placebo after 12 weeks of treatment.
Detailed description
The study will be performed in patients with Nonalcoholic Fatty Liver Disease. The primary endpoint will be the assessment of the change in the percentage of liver fat mass (assessed by MRI-PDFF).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PXL770 | Oral capsule |
| DRUG | Placebo Oral Capsule | Oral capsule |
Timeline
- Start date
- 2019-03-29
- Primary completion
- 2020-08-03
- Completion
- 2020-08-10
- First posted
- 2018-12-04
- Last updated
- 2021-10-28
- Results posted
- 2021-10-28
Locations
15 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03763877. Inclusion in this directory is not an endorsement.